Navigation Links
OncoSec to Present at the 22nd Annual Oppenheimer Healthcare Conference
Date:12/9/2011

SAN DIEGO, Dec. 9, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), a biotechnology company developing advanced-stage OMS ElectroOncology therapies to treat skin cancer and other solid tumor cancers, today announces that Punit Dhillon, President and CEO, will be presenting at the 22nd Annual Oppenheimer Healthcare Conference.

(Logo:  http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

22nd Annual Oppenheimer Healthcare Conference
The Waldorf Astoria
301 Park Avenue
New York, New York 10022
December 13-14, 2011

OncoSec Presentation
December 13, 2011
3:20 pm ET

A live and archived webcast will be accessible on OncoSec's website www.oncosec.com

To arrange a meeting with management please contact Adam Holdsworth, The Investor Relations Group 212-285-3210 aholdsworth@investorrelationsgroup.com

The Oppenheimer 22nd Annual Healthcare Conference will take place at the historic Waldorf Astoria in New York City. This conference will showcase leading public and private companies specializing in sectors such as biotechnology, medical device, pharmaceutical, diagnostics, healthcare tools, facility and distribution. Attendees will be given opportunities to connect to company leaders through formal presentations, panels and one-on-ones giving insight into current healthcare topics of interest from development of new blockbuster pharmaceutical and biotechnology products to Food and Drug Administration policy, M&A environment, and healthcare reform and impact.

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec's clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com. Additional information may also be found at OncoSec's Facebook, Twitter, and LinkedIn sites.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec to Present at 15th Annual Biotech and Specialty Pharmaceuticals Conference
2. OncoSec and Serametrix Collaborate to Identify Potential Biomarkers to Enhance Skin Cancer Immune Therapies
3. OncoSec to Present at Medical Device Investor Forum
4. Device Master File for OncoSec Medical System Completed and Submitted to FDA
5. OncoSec Releases Devices for Use in Clinical Trials
6. Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials
7. OncoSec Announces Positive Results from Head & Neck and Breast Cancer Trials
8. OncoSec Medical to Attend 6th Annual Fire, Ice and Beyond: The Future of Ablation Therapies Conference
9. OncoSec Medical to Present at Industry and Investor Conferences
10. OncoSec Medical Appoints Engineering Leader
11. OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... -- The Rebound mobile app is poised to become a ... of prescription drug addiction. The app empowers users to develop ... down their dosage in a safe, controlled manner while maximizing ... first 100,000 people to sign up will enjoy 3 months ... ...
(Date:9/27/2017)... -- Commended for their devotion to personalized service, SMP Pharmacy Solutions ... in the South Florida Business Journal,s 50 Fastest-Growing Companies, and ... the national specialty pharmacy has found its niche.  To that ... be honored by SFBJ as the 2017 Power Leader in ... receive his award in October, Bardisa said of the three ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... a leader in post-acute health care, have expanded their existing home health joint ... Health. , AccentCare has been operating a joint venture home health company with ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
(Date:10/12/2017)... GRAND RAPIDS, Mich. (PRWEB) , ... October 12, ... ... OnSite Wellness, has been named one of Michigan’s 2017 Best and Brightest in ... Best and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 ...
Breaking Medicine News(10 mins):